USRE39723E1 - Semi-synthetic taxanes with antitumor and antiangiogenetic activities - Google Patents

Semi-synthetic taxanes with antitumor and antiangiogenetic activities Download PDF

Info

Publication number
USRE39723E1
USRE39723E1 US11/158,323 US15832305A USRE39723E US RE39723 E1 USRE39723 E1 US RE39723E1 US 15832305 A US15832305 A US 15832305A US RE39723 E USRE39723 E US RE39723E
Authority
US
United States
Prior art keywords
compound
group
hydrogen
seco
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/158,323
Inventor
Ezio Bombardelli
Alessandro Pontiroli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Priority to US11/158,323 priority Critical patent/USRE39723E1/en
Application granted granted Critical
Publication of USRE39723E1 publication Critical patent/USRE39723E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to seco-baccatin III derivatives.
  • Taxane-skeleton diterpenes in particular Pacliataxel and Docetaxel, are at present used in medicine for the treatment of tumors of different origin.
  • the present invention relates to derivatives of seco-baccatine III, which is disclosed in U.S. Pat. No. 5,756,776, characterized by bioavailability through the oral route, reduced toxicity and extremely high antiangiogentic activity.
  • R 3 is hydrogen, —OR 5 group, wherein R 5 is hydrogen, or it forms with R 2 a carbonate or thiocarbonate residue;
  • R 4 is a benzoyl group optionally substituted at the meta-position, or hetaroyl group
  • R 1 R′ is hydrogen or a C 1 -C 4 alkyl group
  • R 11 R′′ is a C 1 -C 4 alkyl, a C 2 -C 6 alkenyl, aryl or hetaryl;
  • R 111 R′′′ is a C 1 -C 4 alkyl, C 1 -C 18 acyl, aryl group or tert-butoxy group, with the proviso that R and R 1 cannot be both hydrogen.
  • a C 1 -C 18 acyl group is preferably a formyl, acetyl, n-propanoyl, n-hexanoyl group.
  • An optionally substituted aroyl group is preferably benzoyl, optionally substituted with one or three substituents selected from halogen atoms or C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano, nitro groups.
  • a meta-substituted benzoyl group is preferably a 3-halo-benzyl or 3-methoxybenzoyl group.
  • a hetaroyl group is preferably a 5- or 6-membered heteroaryl having one or two oxygen, nitrogen or sulfur atoms in the ring and substituted with a carbonyl group, for example 2- or 3-thenoyl, nicotinoyl, 2- or 3-furoyl.
  • Aryl is preferably phenyl and hetaryl is preferably 2- or 3-furyl, 2- or 3-thienyl, 2- 3- or 4-pyridyl.
  • a preferred group of compounds of formula (I) is that in which:
  • R 2 is hydrogen
  • R 3 is hydrogen
  • R 4 is benzoyl
  • R′ is hydrogen or methyl
  • R′′′ is a tert-butoxy group.
  • a further group of preferred compounds is the one in which R is hydrogen and R 1 is an acyl, aroyl or CONR 6 R 7 group as defined above, R 2 and R 3 are hydrogen, R 4 is benzoyl, R 1 is hydrogen or methyl, R′′ is C 1 -C 4 alkyl or C 2 -C 6 alkenyl and R′′′ is tert-butoxy.
  • the esterification of the hydroxyls at C-7 and C-9 induces, compared with known compounds, an increase in the cytotoxic activity on the resistant cell lines as well as improved absorption through the oral route.
  • the compounds of the invention are less potent than Paclitaxel, taken as the reference drug, in binding with tubulin, while keeping comparable cytotoxicity on the sensitive cancer lines. These compounds mainly differ from those of prior art in the antiangiogenetic activity.
  • Table shows the in vivo activity of some C-seco-10-dehydro-10-deacetyl-7,9-bisacetyl-baccatine III and C-seco-10-dehydro-10-deacetyl-7,9-bisacetyl-1,14-carbonate-baccatine III derivatives having the same isoserine chain.
  • the antiangiogenic activity was evaluated by means of the Matrigel test, in which angiogenesis is induced by FGF-2 (150 mg/pellet) adsorbed on a Matrigel pellet (12.5 mg/ml, 0.5 mL) injected subcutaneously in C57BL6N mice.
  • the tested compound was administered through the oral route daily or through the intraperitoneal route on alternate days, at the shown concentration. After 7 days, the angiogenic response was evaluated by measuring the hemoglobin content in the pellets, according to the procedure by Drabkin.
  • the compounds of the invention are prepared by reacting C-seco-10-dehydro-10-deacetyl-7,9-hydroxy baccatine III described in U.S. Pat. No. 5,756,776 with a carboxylic acid reactive derivative (chloride or anhydride), according to known acylation methods.
  • the C7 and C9 diesters can be prepared by using at least two equivalents of the reactive derivative.
  • the carbamate groups can be introduced with conventional methods, for example by reaction with phosgene and an amine of formula R 6 R 7 NH.
  • the compounds of the invention are characterized by low systemic toxicity: at doses effective in inhibiting the tumor growth they induce neither weight loss nor evident neuro-toxicity; in the nude mouse transplanted with human tumor cells, a dose of Paclitaxel, used as the reference drug, exerting the same antitumor activity, also induces tremors and weight loss up to 20%.
  • the compounds of the present invention thanks to their high water solubility, can be easily formulated in injectable preparations.
  • Compounds (I) can also be formulated in the form of conventional oral compositions (capsules or tablets).
  • compounds (I) can be administered intravenously at dosages up to 600 mg/m 2 and orally at dosages up to 1000 mg/m 2 . Dosages can be decreased to 50 mg/m 2 in the treatment of rheumatoid arthritis.
  • the solvent is evaporated to dryness under vacuum and the residue is taken up in methanol/hydrochloric acid, keeping a temperature of 0° C. for 1 h.
  • the solution is neutralized to pH 5, then diluted with water and the desired compound is back-extracted with CH 2 Cl 2 .
  • the solvent is evaporated off to obtain 700 mg of 13-[(2R, 3S)-3-iso-butyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco 10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III.
  • the solvent is evaporated to dryness under vacuum and the residue is taken up in methanol/hydrochloric acid, keeping a temperature of 0° C. for 1 h.
  • the solution is neutralized to pH 5, then diluted with water and the desired compound is back-extracted with CH 2 Cl 2 .
  • the solvent is evaporated off to obtain 700 mg of 13-[(2R, 3S)-3-iso-butyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III, which is crystallized from ethyl acetate to yield 645 mg of pure compound.
  • the solvent is evaporated to dryness under vacuum and the residue is taken up in methanol/hydrochloric acid, keeping a temperature of 0° C. for 1 h.
  • the solution is neutralized to pH 5, then diluted with water and the desired compound is back-extracted with CH 2 Cl 2 .
  • the solvent is evaporated off to obtain 940 mg of 13-(2R, 3S)-3-isobutyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-trimethoxybenzoyl-baccatine III, which is crystallized from ethyl acetate to yield 878 mg of pure compound.

Abstract

Seco-baccatin III derivatives of formula:
Figure USRE039723-20070710-C00001
wherein R, R1-R4, R1 R′, R11 R″, and R111 R′″ are disclosed herein; pharmaceutical compositions comprising seco-baccatin III derivative; and methods for treating cancer, arthritis, and inhibiting angiogenesis in an animal comprising administrating to a patient in need thereof a therapeutically effective amount of a seco-baccatin III derivative are disclosed.

Description

This application is a continuation of PCT/EP01/00386 dated Jan. 15, 2001.
FIELD OF THE INVENTION
The present invention relates to seco-baccatin III derivatives.
TECHNICAL FIELD
Taxane-skeleton diterpenes, in particular Pacliataxel and Docetaxel, are at present used in medicine for the treatment of tumors of different origin.
However, the presently available taxane derivatives have remarkable side effects and also quickly induce resistance, analogously to other antitumor drugs.
The present invention relates to derivatives of seco-baccatine III, which is disclosed in U.S. Pat. No. 5,756,776, characterized by bioavailability through the oral route, reduced toxicity and extremely high antiangiogentic activity.
SUMMARY OF THE INVENTION
The compounds of the present invention have the following general formula (I)
Figure USRE039723-20070710-C00002
wherein
    • R and R1, which can be the sane same or different, are hydrogen, a C1-C18 acyl group, an optionally substituted aroyl group or a —CONR6R7 wherein R6 and R7, which can be the same or different, are C1-C4 alkyl, benzyl, or phenyl groups;
    • R2 is hydrogen or forms with R3 a carbonate or thiocarbonate residue;
R3 is hydrogen, —OR5 group, wherein R5 is hydrogen, or it forms with R2 a carbonate or thiocarbonate residue;
R4 is a benzoyl group optionally substituted at the meta-position, or hetaroyl group;
R1R′ is hydrogen or a C1-C4 alkyl group;
R11R″ is a C1-C4 alkyl, a C2-C6 alkenyl, aryl or hetaryl;
R111R′″ is a C1-C4 alkyl, C1-C18 acyl, aryl group or tert-butoxy group, with the proviso that R and R1 cannot be both hydrogen.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
A C1-C18 acyl group is preferably a formyl, acetyl, n-propanoyl, n-hexanoyl group.
An optionally substituted aroyl group is preferably benzoyl, optionally substituted with one or three substituents selected from halogen atoms or C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro groups.
A meta-substituted benzoyl group is preferably a 3-halo-benzyl or 3-methoxybenzoyl group.
A hetaroyl group is preferably a 5- or 6-membered heteroaryl having one or two oxygen, nitrogen or sulfur atoms in the ring and substituted with a carbonyl group, for example 2- or 3-thenoyl, nicotinoyl, 2- or 3-furoyl.
Aryl is preferably phenyl and hetaryl is preferably 2- or 3-furyl, 2- or 3-thienyl, 2- 3- or 4-pyridyl.
A preferred group of compounds of formula (I) is that in which:
    • R and R1, which are the same, are a C1-C18 acyl group, an optionally substituted benzoyl group as defined above or a CONR6R7 group, more preferably R and R1 are acetyl or 3,4,5-trimethoxy-benzoyl;
R2 is hydrogen;
R3 is hydrogen;
R4 is benzoyl;
R′ is hydrogen or methyl;
    • R″ is C1-C4 alkyl or C2-C6 alkenyl, more preferably isobutyl or isobutenyl;
R′″ is a tert-butoxy group.
A further group of preferred compounds is the one in which R is hydrogen and R1 is an acyl, aroyl or CONR6R7 group as defined above, R2 and R3 are hydrogen, R4 is benzoyl, R1 is hydrogen or methyl, R″ is C1-C4 alkyl or C2-C6 alkenyl and R′″ is tert-butoxy.
The esterification of the hydroxyls at C-7 and C-9 induces, compared with known compounds, an increase in the cytotoxic activity on the resistant cell lines as well as improved absorption through the oral route. The compounds of the invention are less potent than Paclitaxel, taken as the reference drug, in binding with tubulin, while keeping comparable cytotoxicity on the sensitive cancer lines. These compounds mainly differ from those of prior art in the antiangiogenetic activity. Table shows the in vivo activity of some C-seco-10-dehydro-10-deacetyl-7,9-bisacetyl-baccatine III and C-seco-10-dehydro-10-deacetyl-7,9-bisacetyl-1,14-carbonate-baccatine III derivatives having the same isoserine chain.
The antiangiogenic activity was evaluated by means of the Matrigel test, in which angiogenesis is induced by FGF-2 (150 mg/pellet) adsorbed on a Matrigel pellet (12.5 mg/ml, 0.5 mL) injected subcutaneously in C57BL6N mice.
The tested compound was administered through the oral route daily or through the intraperitoneal route on alternate days, at the shown concentration. After 7 days, the angiogenic response was evaluated by measuring the hemoglobin content in the pellets, according to the procedure by Drabkin.
TABLE
In vivo antiangiogenetic activity of the compound of example II.
Compound Hemoglobin g/dl %
Control  0.01 ± 0.001 —
FGF-2  0.03 ± 0.001 +300
Example II
90 mg/kg i.p. 0.015 ± 0.001 −50
150 mg/kg p.o. 0.009 ± 0.001 −70
Example VII
50 mg/kg i.p. 0.014 −40
100 mg/kg p.o. 0.009 −70
The compounds of the invention are prepared by reacting C-seco-10-dehydro-10-deacetyl-7,9-hydroxy baccatine III described in U.S. Pat. No. 5,756,776 with a carboxylic acid reactive derivative (chloride or anhydride), according to known acylation methods.
The C7 and C9 diesters can be prepared by using at least two equivalents of the reactive derivative. The carbamate groups can be introduced with conventional methods, for example by reaction with phosgene and an amine of formula R6R7NH.
The resulting compounds are then reacted, according to known procedures, with an isoserine derivative, usually an oxazolidine derivative, which, by acid treatment under mild conditions gives compounds (I).
The compounds of the invention are characterized by low systemic toxicity: at doses effective in inhibiting the tumor growth they induce neither weight loss nor evident neuro-toxicity; in the nude mouse transplanted with human tumor cells, a dose of Paclitaxel, used as the reference drug, exerting the same antitumor activity, also induces tremors and weight loss up to 20%.
The compounds of the present invention, thanks to their high water solubility, can be easily formulated in injectable preparations.
Compounds (I) can also be formulated in the form of conventional oral compositions (capsules or tablets).
Thanks to their low toxicity, compounds (I) can be administered intravenously at dosages up to 600 mg/m2 and orally at dosages up to 1000 mg/m2. Dosages can be decreased to 50 mg/m2 in the treatment of rheumatoid arthritis.
The following examples further illustrate the invention without limiting its scope.
EXAMPLE I Preparation of C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III
A solution of 300 mg of 10-dehydro-10-deacetylbaccatine III in 5 ml of methanol is added with 1 equiv. of CeCl3.3H2O and the reaction mixture is stirred for 10 min. After complete dissolution, 80 mg of NaBH4 are added in small portions. After 10 min the solution is treated with an equal volume of a NH4Cl aqueous solution and extracted with CH2Cl2. The chlorinated solvent is removed, the residue is taken up in 1 ml of pyridine, cooled to 0° C. in 1 h, then added with 150 mg of acetic anhydride. The solution is left to stand for 2 h at 0° C., then diluted with 10 ml of water and back-extracted with CH2Cl2. The chlorinated solvent is distilled off under vacuum and the residue is chromatographed on silica gel eluting with a mixture of n-hexane/ethyl acetate to obtain 260 mg of C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III (m/z 630).
EXAMPLE II Preparation of 13-[(2R, 3S)-3-iso-butyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III
630 mg of C-sero-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III are dissolved in 5 ml of toluene and added with 335 mg of dicyclohexylcarbodiimide (DCC), 500 mg of (4S,5R)-N-Boc-2-(2,4-dimethoxyphenyl)-4isobutyl-5-oxazolidine-carboxylic acid and 20 mg of 4-dimethylaminopyridine. The solution is heated at 60° C. for 24 h, then treated with ethyl acetate and a NaHCO3 saturated solution. The organic phase is dried and filtered through silica gel to remove urea. The solvent is evaporated to dryness under vacuum and the residue is taken up in methanol/hydrochloric acid, keeping a temperature of 0° C. for 1 h. The solution is neutralized to pH 5, then diluted with water and the desired compound is back-extracted with CH2Cl2. The solvent is evaporated off to obtain 700 mg of 13-[(2R, 3S)-3-iso-butyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco 10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III.
EXAMPLE III Preparation of 13-[(2R, 3S)-3-phenyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III
630 mg of C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III are dissolved in 5 ml of toluene and added with 335 mg of DCC, 525 mg of (4S,5R)-N-Boc-2-(2,4-dimethoxyphenyl)4-isobutyl-5-oxazolidine-carboxylic acid and 20 mg of 4dimethylaminopyridine. The solution is heated at 60° C. for 24 h, then treated with ethyl acetate and a NaHCO3 saturated solution. The organic phase is dried and filtered through silica gel to remove urea. The solvent is evaporated to dryness under vacuum and the residue is taken up in methanol/hydrochloric acid, keeping a temperature of 0° C. for 1 h. The solution is neutralized to pH 5, then diluted with water and the desired compound is back-extracted with CH2Cl2. The solvent is evaporated off to obtain 700 mg of 13-[(2R, 3S)-3-iso-butyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III, which is crystallized from ethyl acetate to yield 645 mg of pure compound.
EXAMPLE IV Preparation of C-seco-10-dehydro-10-deacetyl-7,9-bis-trimethoxybenzoyl-baccatine III
A solution of 546 mg of C-seco-10-dehydro-10-deacetyl-baccatine III in 3 ml of pyridine is added with 575 mg of trimethoxybenzoyl chloride in small portions. After 3 h the solution is poured into 30 ml of water and extracted with CH2Cl2; the organic phase is washed with acids until pyridine is completely removed. The solvent is evaporated off to obtain 905 mg of C-seco-10-dehydro-10-deacetyl-7,9-bis-trimethoxybenzoyl-baccatine III. (m/z 936).
EXAMPLE V Preparation of 13-[(2R, 3S)-3-phenyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10deacetyl-7,9-bis-trimethoxybenzoyl-baccatine III
930 mg of 13-[(2R, 3S)]-C-seco-10-dehydro-10-deacetyl-7,9-bis-trimethoxy-benzoyl-baccatine III are dissolved in 15 ml of toluene and added with 335 mg of DCC, 525 mg of (4S, 5R)-N-boc-2-(2,4-dimethoxyphenyl)4isobutyl-5-oxazolidinecarboxylic acid and 20 mg of 4-dimethylaminopyridine. The solution is heated at 60° C. for 24 h, then treated with ethyl acetate and a NaHCO3 saturated solution. The organic phase is dried and filtered through silica gel to remove urea. The solvent is evaporated to dryness under vacuum and the residue is taken up in methanol/hydrochloric acid, keeping a temperature of 0° C. for 1 h. The solution is neutralized to pH 5, then diluted with water and the desired compound is back-extracted with CH2Cl2. The solvent is evaporated off to obtain 940 mg of 13-(2R, 3S)-3-isobutyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-trimethoxybenzoyl-baccatine III, which is crystallized from ethyl acetate to yield 878 mg of pure compound.
EXAMPLE VI Preparation of C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III 1,14-carbonate
1 g of 10-deacetyl-14β-hydroxybaccatine III 1,14 carbonate, prepared as disclosed in U.S. Pat. No. 5,698,712, are dissolved in methanol and treated with 6 g of Cu(OAc)2 and the reaction mixture is stirred for 120 hrs. The salt is filtered off, the solvent is removed and the residue is chromatographed on silica gel column, eluting with a 6:4 mixture of hexane/ethyl acetate, to obtain 0.9 g of 10-dehydro-10-deactyl-14,β-hydroxy-baccatine III 1,14carbonate (M+568). 300 mg of this compound are dissolved in methanol and treated with 1 equiv. of CeCl3.3H2O and the reaction mixture is stirred for 10 min. After complete dissolution, 80 mg of NaBH4 are added in small portions. After 10 min the solution is treated with an equal volume of a NH4Cl aqueous solution and extracted with CH2Cl2. The chlorinated solvent is removed, the residue is taken up in 1 ml of pyridine, cooled to 0° C. in 1 h, then added with 150 mg of acetic anhydride under stirring. The solution is left to stand for 2 h at 0° C., then diluted with 10 ml of water and back-extracted with CH2Cl2. The chlorinated solvent is distilled off under vacuum and the residue is chromatographed on silica gel eluting with a mixture of n-hexane/ethyl acetate to obtain 250 mg of C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III 1,14-carbonate (m/z 658).
EXAMPLE VII Preparation of 13-[(2R, 3S)-3-isobutyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III 1,14-carbonate
600 mg of C-seco-10-dehydro-10-deacetyl-7,9-bis-acetyl-baccatine III 1,14-carbonate are treated as described in Example II, to obtain 680 mg of the title compound.

Claims (20)

1. A compound of formula:
Figure USRE039723-20070710-C00003
wherein R and R1 are each independently hydrogen, a C1-C18 acyl group, an aroyl group which may be substituted or unsubstituted, or —CONR6R7;
R2 is hydrogen or R2 forms a carbonate or thiocarbonate with R3;
R3 is hydrogen, hydrogen or —OH, or R3 forms a carbonate or thiocarbonate with R2;
R4 is a benzoyl group which is unsubstituted or substituted at the meta position or a hetaroyl group;
R6 and R7 are a C1-C4 alkyl group, a benzyl group, or a phenyl group;
R1R′ is hydrogen or a C1-C4 alkyl group;
R11R″ is a C1-C4 alkyl group, a C2-C6 alkenyl group, an aryl group, or a hetaryl group; and
R111R′″ is a C1-C4 alkyl group, a C1-C18 acyl group, an aryl group, or a tert-butoxy group, with the proviso that both R and R1 cannot be hydrogen.
2. The compound of claim 1, wherein both R and R1 are a C1-C18 acyl group, an aroyl group which may be substituted or unsubstituted, or —CONR6R7;
R2 is hydrogen;
R3 is hydrogen;
R4 is benzoyl;
R1R′ is hydrogen or methyl;
R11R″ is a C1-C4 alkyl group or a C2-C6 alkenyl group; and
R111R′″ is a tert-butoxy group.
3. The compound of claim 2, wherein R and R1 are acetyl or 3,4,5-trimethoxybenzoyl.
4. The compound of claim 2, wherein R11 R″ is isobutyl or isobutenyl.
5. The compound of claim 1, wherein R and R1 are acetyl or 3,4,5-trimethoxybenzoyl and R11 R″ is isobutyl or isobutenyl.
6. The compound of claim 1, wherein R is hydrogen;
R1 is a C1-C18 acyl group, an aroyl group which may be substituted or unsubstituted, or —CONR6R7;
R2 and R3 are hydrogen;
R4 is benzoyl;
R1R′ is hydrogen or methyl;
R11R″ is a C1-C4 alkyl group, a C2-C6 alkenyl group; and
R111R′″ is a tert-butoxy group.
7. The compound of claim 1, selected from the group consisting of
13-[(2R, 3S)-3-iso-butyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehyrdo-10-deacetyl-7,9-bis-acetyl-baccatine III
13-[( 2R, 3S)- 3 -iso-butyl- 2 -hydroxy- 3 -tert-butoxycarbonylamino-propanoyl]-C-seco- 10 -dehydro- 10 -deacetyl- 7,9 -bis-acetyl-baccatine III;
13-[(2R, 3S)-3-phenyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehyrdo-10-deacetyl-7,9-bis-acetyl-baccatine III
13-[( 2R, 3S)- 3 -phenyl- 2 -hydroxy- 3 -tert-butoxycarbonylamino-propanoyl]-C-seco- 10 -dehydro- 10 -deacetyl- 7,9 -bis-acetyl-baccatine III;
13-[(2R, 3S)-3-phenyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehyrdo-10-deacetyl-7,9-bis-trimethoxybenzoyl-baccatine III
13-[( 2R, 3S)- 3 -phenyl- 2 -hydroxy- 3 -tert-butoxycarbonylamino-propanoyl]-C-seco- 10 -dehydro- 10 -deacetyl- 7,9 -bis-trimethoxybenzoyl-baccatine III;
13-[(2R, 3S)-3-phenyl-2-hydroxy-3-tert-butoxycarbonylamino-propanoyl]-C-seco-10-dehyrdo-10-deacetyl-7,9-bis-acetyl-baccatine III 1,14-carbonate
13-[( 2R, 3S)- 3 -phenyl- 2 -hydroxy- 3 -tert-butoxycarbonylamino-propanoyl]-C-seco- 10 -dehydro- 10 -deacetyl- 7,9 -bis-acetyl-baccatine III 1,14 -carbonate.
8. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.
15. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
16. The method of claim 15, wherein the compound is administered to the patient intravenously in an amount of up to 600 mg/m2.
17. The method of claim 15, wherein the compound is administered to the patient orally in an amount of up to 1000 mg/m2.
18. A method of treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
19. The method of claim 18, wherein the compound is administered to the patient in an amount of up to 50 mg/m2.
20. A method of inhibiting angiogenesis comprising administering to a patient in need there of a therapeutically effective amount of the compound of claim 1.
US11/158,323 2000-01-18 2005-06-20 Semi-synthetic taxanes with antitumor and antiangiogenetic activities Expired - Lifetime USRE39723E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/158,323 USRE39723E1 (en) 2000-01-18 2005-06-20 Semi-synthetic taxanes with antitumor and antiangiogenetic activities

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT2000MI000056A IT1317731B1 (en) 2000-01-18 2000-01-18 SEMISYNTHETIC TASSANI WITH ANTI-TUMOR AND ANTIANGIOGENETIC ACTIVITY.
PCT/EP2001/000386 WO2001053282A1 (en) 2000-01-18 2001-01-15 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
US10/187,995 US6589979B2 (en) 2000-01-18 2002-07-03 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
US11/158,323 USRE39723E1 (en) 2000-01-18 2005-06-20 Semi-synthetic taxanes with antitumor and antiangiogenetic activities

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/187,995 Reissue US6589979B2 (en) 2000-01-18 2002-07-03 Semi-synthetic taxanes with antitumor and antiangiogenetic activities

Publications (1)

Publication Number Publication Date
USRE39723E1 true USRE39723E1 (en) 2007-07-10

Family

ID=11443708

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/187,995 Ceased US6589979B2 (en) 2000-01-18 2002-07-03 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
US11/158,323 Expired - Lifetime USRE39723E1 (en) 2000-01-18 2005-06-20 Semi-synthetic taxanes with antitumor and antiangiogenetic activities

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/187,995 Ceased US6589979B2 (en) 2000-01-18 2002-07-03 Semi-synthetic taxanes with antitumor and antiangiogenetic activities

Country Status (24)

Country Link
US (2) US6589979B2 (en)
EP (1) EP1248776B1 (en)
JP (1) JP4986354B2 (en)
KR (1) KR100813704B1 (en)
CN (1) CN1176916C (en)
AT (1) ATE271044T1 (en)
AU (1) AU781650B2 (en)
CA (1) CA2397591C (en)
CZ (1) CZ301251B6 (en)
DE (1) DE60104281T2 (en)
DK (1) DK1248776T3 (en)
ES (1) ES2223778T3 (en)
HK (1) HK1049998B (en)
HU (1) HU229347B1 (en)
IL (1) IL150787A0 (en)
IT (1) IT1317731B1 (en)
NO (1) NO329403B1 (en)
PL (1) PL202591B1 (en)
PT (1) PT1248776E (en)
RU (1) RU2259363C2 (en)
SI (1) SI1248776T1 (en)
SK (1) SK285683B6 (en)
TR (1) TR200401811T4 (en)
WO (1) WO2001053282A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688415A1 (en) * 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
ITMI20050415A1 (en) * 2005-03-15 2006-09-16 Indena Spa SEMI-SYNTHETIC TOXIC DERIVATIVES WITH ANTITUMOR ACTIVITY
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3888691A1 (en) 2016-11-14 2021-10-06 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003394A1 (en) 1994-07-26 1996-02-08 Indena S.P.A. Semi-synthetic taxanes with anti-tumoural activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175315A (en) * 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003394A1 (en) 1994-07-26 1996-02-08 Indena S.P.A. Semi-synthetic taxanes with anti-tumoural activity
US5756776A (en) * 1994-07-26 1998-05-26 Indena S.P.A. Semi-synthetic taxanes with anti-tumoural activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Appendino et al., Synthesis and Evaluation of C-seco Paclitaxel Analogs, Tetrahedron Letters, 38(24):4273-4276 (1997). See p. 4274, compounds 5a-5d. *
Distenfano et al., Antitumor Activity of Paclitaxel (Taxol) Analogs on MDR-positive Human Cancer Cells, Anti-Cancer Drug Design 13(5):489-499 (1998). *
International Search Report of PCT/EP01/00386.
Lainer, et al., "New antiangiogenic strategies for the treatment of proliferative synovitis", Expert Opinion Investig. Drugs (2005), 14(1), pp. 1-17. *
Wang et al., The Oxetane Ring in Taxol, J. Org. Chem., 65:1059-1068 (2000). *

Also Published As

Publication number Publication date
SK10562002A3 (en) 2002-11-06
AU781650B2 (en) 2005-06-02
US20030028038A1 (en) 2003-02-06
ITMI20000056A0 (en) 2000-01-18
NO20023428D0 (en) 2002-07-17
IT1317731B1 (en) 2003-07-15
JP2003520792A (en) 2003-07-08
IL150787A0 (en) 2003-02-12
EP1248776B1 (en) 2004-07-14
CN1176916C (en) 2004-11-24
HUP0204344A2 (en) 2003-05-28
NO329403B1 (en) 2010-10-11
SI1248776T1 (en) 2004-10-31
ES2223778T3 (en) 2005-03-01
SK285683B6 (en) 2007-06-07
HU229347B1 (en) 2013-11-28
CZ20022478A3 (en) 2002-10-16
CZ301251B6 (en) 2009-12-23
ITMI20000056A1 (en) 2001-07-18
KR100813704B1 (en) 2008-03-13
JP4986354B2 (en) 2012-07-25
RU2259363C2 (en) 2005-08-27
NO20023428L (en) 2002-09-16
CA2397591A1 (en) 2001-07-26
HUP0204344A3 (en) 2004-01-28
KR20020068082A (en) 2002-08-24
DE60104281T2 (en) 2005-08-18
HK1049998A1 (en) 2003-06-06
RU2002119060A (en) 2004-01-10
PL356272A1 (en) 2004-06-28
WO2001053282A1 (en) 2001-07-26
EP1248776A1 (en) 2002-10-16
CA2397591C (en) 2009-10-20
US6589979B2 (en) 2003-07-08
PT1248776E (en) 2004-10-29
ATE271044T1 (en) 2004-07-15
PL202591B1 (en) 2009-07-31
AU3369401A (en) 2001-07-31
CN1395571A (en) 2003-02-05
HK1049998B (en) 2005-04-01
TR200401811T4 (en) 2004-09-21
DE60104281D1 (en) 2004-08-19
DK1248776T3 (en) 2004-11-22

Similar Documents

Publication Publication Date Title
RU2137764C1 (en) Taxane derivatives, method of their synthesis, pharmaceutical composition and method of treatment
AU730174B2 (en) Novel taxane derivatives
USRE39723E1 (en) Semi-synthetic taxanes with antitumor and antiangiogenetic activities
WO1998008833A1 (en) Sulfenamide taxane derivatives
HU218665B (en) Baccatine-iii derivatives, pharmaceuticals containing them as active agent and process for producing them
US6750246B1 (en) C-4 carbonate taxanes
KR100388877B1 (en) 10-DEACTYLBACCATINE Ⅲ AND 10-DEACETYL 14β-HYDROXYBACCATINE Ⅲ DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5547981A (en) Taxol-7-carbazates
US20050250844A1 (en) Methods of treating cancer using C-4 carbonate taxanes
JP2003522172A (en) C10 ester-substituted taxanes as antitumor agents
WO1998037765A1 (en) 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
WO2009062342A1 (en) Cephalomannine derivatives and their preparation, medicinal composition and use
WO1999032109A1 (en) 7-deoxy-6-nitrogen substituted paclitaxels
CA2456523A1 (en) C-2' methylated derivatives of paclitaxel for use as antitumour agents

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12